[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"craniopharyngioma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:craniopharyngioma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,48,77,103,126,156,187,210,240],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100617244","clinical-trial-of-an-anti-fog-drainage-device-for-endoscopic-endonasal-sellar-region-tumor-surgery-100617244",false,"NCT07316101","Clinical Trial of an Anti-Fog Drainage Device for Endoscopic Endonasal Sellar Region Tumor Surgery","Inclusion Criteria:\n\n* Age 18-75 years\n* Pre-operative MRI\u002FCT diagnosis of pituitary adenoma or craniopharyngioma ≤ \\*3 cm without extensive skull-base invasion\n* Scheduled for elective endoscopic endonasal transsphenoidal resection\n* ASA physical status I-III\n* Able and willing to give written informed consent and comply with follow-up\n\nExclusion Criteria:\n\n* Severe nasal anatomical deformity, polyps, or prior nasal surgery preventing device placement\n* Active nasal or systemic infection (WBC \\> 10 × 10⁹\u002FL, CRP ≥ 10 mg\u002FL)\n* Known intracranial infection or ongoing CSF leak\n* Coagulopathy (PT \\> 14 s or APTT \\> 45 s) or anticoagulation that cannot be stopped ≥ 7 days\n* Allergy to silicone or medical-grade plastics\n* Planned combined transcranial or transorbital approach\n* Pregnancy or breastfeeding\n* Psychiatric or cognitive disorder precluding informed consent or follow-up","ALL","18 Years","75 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if the anti-fog suction device works to keep the surgical view clear during endoscopic nose-to-pituitary operations and whether it lowers the chance of brain-fluid infection. It will also learn about the safety of the device.\n\nThe main questions it aims to answer are:\n\n* Does the device reduce the total time the surgeon has to stop because the lens fogs up?\n* What medical problems (such as nose-bleed, tube blockage, or infection) do participants have when the device is used?\n\nResearchers will compare the anti-fog device to the usual \"water-squirt\" method to see if the device works better.\n\nParticipants will:\n\n* Have either the device or the usual water method applied during their planned pituitary surgery\n* Stay in the hospital for the normal recovery period (about 3-5 days) and return for a routine check-up around day 7\n* Allow the study team to record operating times, any fog-related pauses, and results of blood or spinal-fluid tests taken before and after surgery",[26,27],"Pituitary Adenoma","Craniopharyngioma",[29,30,31,32,33,34],"endoscopic endonasal surgery","pituitary adenoma","anti-fog device","suction irrigation","intracranial infection","randomized controlled trial","RECRUITING","2026-06-26",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"2026-03-01",{"date":43,"type":20},"2026-12-31",{"name":45,"class":46},"West China Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":19},"100474997","phase-2-tovorafenib-for-treatment-of-craniopharyngioma-in-children-and-young-adults-100474997","NCT05465174","Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults","Tovorafenib for the Treatment of Newly Diagnosed or Recurrent Craniopharyngioma in Children and Young Adults","PNOC029","Inclusion Criteria:\n\nNewly Diagnosed Participants:\n\n* Newly diagnosed craniopharyngioma, as based on imaging characteristics and central radiology review. Participants will initially be screened within confines of a screening consent and only those participants with findings consistent with craniopharyngioma and without findings suggesting an indeterminate lesion or lesion of an alternative diagnosis (including abnormal tumor markers found in blood or cerebral spinal fluid (CSF), if completed as part of standard of care (SOC) work-up or if lesion concerning for alternate diagnosis) will move ahead with enrollment on the treatment protocol. Additionally, for participants that have undergone initial biopsy to confirm diagnosis, are within 6 weeks of radiographic diagnosis, and are planned to undergo follow up second surgery for additional tumor resection as per standard of care recommendations, these participants will also be considered eligible.\n* Participants must be surgical candidates for biopsy or resection and planned for standard of care biopsy or resection.\n\nRecurrent Participants:\n\n* Recurrent craniopharyngioma, as based on histologic confirmation at time of initial diagnosis (participants with Adamantinomatous craniopharyngioma (ACP) will only be eligible for the recurrent arm).\n* Recurrent craniopharyngioma without prior histologic confirmation will initially be screened within confines of a screening consent and only those participants with findings consistent with craniopharyngioma and without findings suggesting an indeterminate lesion or lesion of an alternative diagnosis (including abnormal tumor markers found in blood or CSF, if completed as part of SOC work-up or if lesion concerning for alternate diagnosis) will move ahead with enrollment on the treatment protocol.\n* Participants should be surgical candidates for biopsy or resection. If participants are not surgical candidates, but have available archival tumor tissue, they will be enrolled into the exploratory cohort.\n* Participants must be willing to provide archival tissue, a minimum of 10-20 paraffin embedded unstained slides OR 1 block with tumor content of 40% or greater is required. Participants who do not meet this criteria may be discussed on a case-by-case basis with the Study Chair(s).\n* Participants can have been previously treated with surgical resection alone, cyst drainage and biopsy alone, radiation therapy, other systemic therapies, or any combination thereof.\n* Prior Therapy:\n\n  * Had their last dose of myelosuppressive chemotherapy \\>= 21 days prior to study registration (\\>=42 days if nitrosourea therapy).\n  * Had their last dose of hematopoietic growth factor \\>=14 days (long-acting growth factor) or \\>=7 days (short-acting growth factor) prior to study registration, or beyond the time during which adverse events (AEs) are known to occur.\n  * Had their last dose of biologic (anti-neoplastic agent) \\>=7 days prior to study registration, or beyond the time during which AEs are known to occur.\n  * Had their last dose of monoclonal antibodies \\>=21 days prior to study registration.\n\nRadiation:\n\n* Had their last fraction of local irradiation to primary tumor \\>=12 weeks prior to registration; investigators are reminded to review potentially eligible cases to avoid confusion with pseudo-progression.\n* At least 14 days after local palliative radiation (small-port).\n\nAll Participants:\n\n* Age 1 to 39 years.\n* Participants continuing on maintenance therapy after standard of care biopsy\u002Fresection must have measurable disease, as defined as lesions that can be accurately measured in two dimensions (longest diameter to be recorded) with a minimum size of no less than double the slice thickness. Previously irradiated lesions are considered non-measurable except in cases of documented progression of the lesion since the completion of radiation therapy. Participants without measurable disease may continue on study and will be followed for study endpoints, but will not be included as part of target accrual.\n* Performance Score: Karnofsky \\>= 50 for participants \\> 16 years of age and Lansky \\>= 50 for participants \\\u003C= 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.\n* Corticosteroids: Participants who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration. The participant steroid dose should be no more than a steroid-equivalent of dexamethasone 0.1 mg\u002Fkg\u002Fday (or maximum 4mg\u002Fday; whichever is the lower dose) at time of enrollment. Participants that have been stable on physiologic hormone replacement for hypopituitarism are allowed.\n* Organ Function Requirements:\n\n  * Adequate Bone Marrow Function defined as:\n\n    * Peripheral absolute neutrophil count (ANC) \\>=1000\u002Fmm3.\n    * Platelet count \\>= 100,000\u002Fmm3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment).\n  * Adequate Renal Function defined as-\n\n    ---A serum creatinine \\\u003C 1.5 Upper Limit normal (ULN) based on age and gender.\n  * Adequate Liver Function defined as-\n\n    * Bilirubin (sum of conjugated + unconjugated) \\\u003C= 1.5 x upper limit of normal (ULN) for age (except in participants with documented Gilbert syndrome).\n    * Serum glutamic-pyruvic transaminase (SGPT)((alanine aminotransferase (ALT)) \\\u003C= 3 x ULN.\n    * Serum albumin \\>=2 g\u002FdL (20g\u002FL).\n  * Adequate Neurologic Function defined as participants with seizure disorder may be enrolled if well controlled. Participants on non-enzyme inducing anticonvulsants may be excluded pending interaction(s) with study drug.\n  * Adequate Pulmonary Function defined as no evidence of dyspnea at rest, no exercise intolerance due to pulmonary insufficiency, and a pulse oximetry of \\> 92% while breathing room air.\n  * prothrombin time (PT) \u002Fpartial thromboplastin time (PTT)\u002FInternational Normalized Ratio (INR) within institutional normal limits or deemed appropriate for surgical intervention by the treating team for patients undergoing surgery biopsy\u002Fresection\n* The effects of Tovorafenib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (non-hormonal contraception; barrier method of birth control; abstinence - note, tovorafenib can make hormonal contraceptives ineffective) prior to study entry, for the duration of study participation and 28 days after completion of Tovorafenib administration, whichever is later. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* A legal parent\u002Fguardian or participants must be able to understand, and willing to sign, a written informed consent and assent document, as appropriate.\n* Ability to complete the PedsQL Core Module.\n* Patients must enroll on PNOC COMP if PNOC COMP is open to accrual at the enrolling institution.\n\nExclusion Criteria:\n\nNewly Diagnosed Participants:\n\n\\- Participants should not have undergone any previous tumor-directed therapy.\n\nRecurrent Participants:\n\n* Participants who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from acute adverse events due to agents administered more than 4 weeks earlier.\n* Participants must be at least 1 week since the completion of therapy with a biologic or small molecule agent. For any agent with known adverse events that can occur beyond 1 week after administration, the period prior to enrollment must be beyond the time during which adverse events are known to occur. Such participants should also be discussed with study chairs.\n* Participants should not have previously received any RAS-pathway, but have not received Tovorafenib will be eligible.\n\nAll Participants:\n\n* Rapidly progressive symptoms that require urgent surgery or radiation therapy, which would prevent central review and or preclude participation with tumor-directed medical management alone.\n* Uncontrolled symptoms of neuroendocrine dysfunction such as diabetes insipidus, hypothyroidism, panhypopituitarism (participants can be on supplemental medications for hormonal repletion; however, should be on controlled doses for at least 2 weeks prior to enrollment).\n* Clinically significant active cardiovascular disease, or history of myocardial infarction, or deep vein thrombosis\u002Fpulmonary embolism within 6 months prior to registration, ongoing cardiomyopathy, or current prolonged QT interval corrected for heart rate by Fridericia's formula (QTcF) interval \\> 440 ms based on triplicate ECG average.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to tovorafenib.\n* Nausea and vomiting \\>= Grade 2, malabsorption requiring supplementation, or significant bowel or stomach resection that would preclude adequate absorption.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection.\n* Participants who are receiving any other investigational agents.\n* Women of childbearing potential must not be pregnant or breast-feeding.\n* Current treatment with a strong cytochrome P4502C8(CYP2C8) inhibitor or inducer other than those allowed per Section 5.6.1. Medications that are substrates of CYP2C8 are allowed but should be used with caution.\n* Participants with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.","1 Year","39 Years",{"count":59,"type":20},57,[61],"PHASE2","The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.",[64,27,65],"Craniopharyngioma, Child","Recurrent Craniopharyngioma",[67],"Neoadjuvant therapy","2026-04-21",{"date":70,"type":39},"2026-04-23",{"date":72,"type":39},"2022-09-12",{"date":74,"type":20},"2028-03-01",{"name":76,"class":46},"Sabine Mueller, MD, PhD",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":47},"100616126","food-preferences-and-craniopharyngiomas-100616126","NCT07301554","Food Preferences and Craniopharyngiomas","Evaluation of Food Preferences in Patients Treated Surgically for Craniopharyngiomas","PREFAMHYPO","Inclusion Criteria:\n\n* Common inclusion criteria: complete medical record accessible, capacity to understand and complete self-administered questionnaires, agreement to complete the questionnaires at the time of inclusion, adult subject, not in an emergency situation, provision of non-opposition (opt-out consent documented), affiliation to a social security scheme.\n\nInclusion (Phase 1): Adults residing in France, aged 18 - 74 years from the general population.\n\nInclusion (Phase 2): Adults aged 18 - 74 years;\n\nGroup 1: patients with craniopharyngioma surgery ≥ 3 months prior to inclusion.\n\nGroup 2: patients with pituitary macroadenoma surgery with documented ≥ 2 anterior pituitary deficits.\n\nGroup 3: Follow-up for an endocrine condition without hypothalamo-hypophyseal involvement, acceptable conditions (thyroid nodule without dysthyroidism, PCOS, peripheral hirsutism, calcium metabolism disorders), no known treatments or prior medical history likely to influence eating behaviour.\n\nExclusion Criteria:\n\n* Common exclusion criteria: bariatric surgery, GLP-1 agonist treatment, chronic disease affecting alimentation, pregnancy or breastfeeding, specific diets (gluten-free, vegetarian, vegan...), refusal or opposition to data use, vulnerability status (under guardianship or legal protection) or inability to complete questionnaires or to understand the proposed research or to express a clear opinion regarding non-opposition.\n\nAdditional exclusion criteria:\n\nphase 1: Type 1 or type 2 diabetes, Active smoking, alcohol misuse, drug use, diagnosed psychiatric disorders or eating behaviour disorders.\n\nPhase 2:\n\nPerson benefiting from State Medical Aid (AME).\n\nControl group:\n\nHypothalamo-hypophyseal pathology, type 1 or type 2 diabetes, uncontrolled hyperthyroidism or hypothyroidism, adrenal hormone hypersecretion disorder, history of or ongoing treatment for active cancer.",{"count":86,"type":20},346,"OBSERVATIONAL","The hypothalamus plays a key role in regulating appetite, satiety, and energy balance. When tumors such as craniopharyngiomas develop in this region, they can disrupt these mechanisms and lead to a form of severe weight gain known as hypothalamic obesity. Several factors play a role in the development of hypothalamic obesity that is often resistant to traditional treatments. Changes in food preferences notably a higher liking for food rich in fat and sugar may be implicated as has been reported in common obesity.\n\nThe working hypothesis of the study is that hypothalamic lesions may alter food preferences, leading to an increased preference for high-fat and high-sugar foods, and that these changes in dietary choices contribute among other factors to the development of hypothalamic obesity.\n\nBy providing the first evaluation of food preferences in adults treated surgically for craniopharyngiomas, this study will shed light on the role of hypothalamic lesions in modifying dietary choices. The results may help explain why some patients experience rapid and resistant weight gain, and could guide future strategies to better manage hypothalamic obesity.",[27],[27,91,92],"food preferences","changes","NOT_YET_RECRUITING","2026-02-20",{"date":96,"type":39},"2026-02-23",{"date":98,"type":20},"2026-02",{"date":100,"type":20},"2028-12",{"name":102,"class":46},"Assistance Publique - Hôpitaux de Paris",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":15,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":124,"locationsCount":47},"100606586","immunopet-targeting-trophoblast-cell-surface-antigen-2-trop-2-in-craniopharyngioma-patients-100606586","NCT07177482","ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients","Inclusion criteria:\n\n* must be able to provide a written informed consent\n* radiologically presumed and\u002For histologically confirmed craniopharyngioma scheduled for resection\n* adequate clinical condition (Karnofsky performance status ≥70)\n\nExclusion criteria:\n\n* concomitant major central nervous system disorders\n* severe hepatic or renal dysfunction\n* history of severe allergy or hypersensitivity to intravenous radiographic contrast agents\n* claustrophobia precluding PET\u002FCT or MRI examinations\n* pregnancy or breastfeeding","14 Years","80 Years",{"count":19,"type":20},[23],"This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.",[27],[116,117],"Positron-Emission Tomography","Diagnosis","2025-09-10",{"date":120,"type":39},"2025-09-17",{"date":122,"type":39},"2025-07-04",{"date":43,"type":20},{"name":125,"class":46},"Deling Li",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":15,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100539134","phase-2-efficacy-and-safety-of-phenterminetopiramate-in-youth-with-hypothalamic-obesity-100539134","NCT06299891","Efficacy and Safety of Phentermine\u002FTopiramate in Youth With Hypothalamic Obesity","Phentermine\u002FTopiramate in Children, Adolescents, and Young Adults With Hypothalamic Obesity: a Pilot and Feasibility Study","Inclusion Criteria:\n\n1. Males and Females; Ages 6-28 years (inclusive)\n2. History of rapid weight gain related to tumor onset or treatment, as assessed by an experienced endocrinologist (for example, change in BMI z-score \\> 0.2 and\u002For BMI +5% during the first 6 months following tumor treatment)\n3. Obesity (BMI \\> 95th%ile for age\u002Fsex using CDC 2000 reference for under 18; BMI \\> 30 kg\u002Fm2 for 18+ years)\n4. Recent evidence of hypothalamic injury by brain MRI with central review; \\>6 months status-post definitive therapy (surgery, chemotherapy, or radiation); no major operations\u002Fsurgeries planned during the study period.\n5. Stable on pituitary replacement\\* and\u002For appetite-modulating medications (including stimulants) for at least 2 months. \\*Adjustments of less than 25% (\\\u003C25%) are permitted to hydrocortisone, growth hormone or thyroid hormone. Sex steroids and DDAVP are exempt.\n6. Post-menarchal females must use a highly effective form of contraception, unless hypogonadotropic hypogonadism is documented. All participating females of child-bearing potential will have pregnancy testing as outlined in the protocol.\n7. Participants must be able to communicate well with the investigative team, must comply with requirements of the study, and be able to provide written informed consent and\u002For assent for individuals less than 18y with consent of a parent\u002Flegal guardian.\n\nExclusion Criteria:\n\n1. Contraindication to Phentermine, Topiramate, or Qsymia as assessed using current package inserts. Including: History of glaucoma and known hyperthyroidism.\n2. Known history of nephrolithiasis (kidney stones).\n3. Current clinical diagnosis of anorexia nervosa or bulimia nervosa in the medical record.\n4. Known history of metabolic acidosis, low bicarbonate on screening laboratory assessment (below lower limit of normal), or clinically significant bone disease requiring medication (beyond calcium and\u002For vitamin D).\n5. Current or recent (\\\u003C14 days) use of monoamine oxidase inhibitor.\n6. Known hypersensitivity to sympathomimetic amines.\n7. Clinically significant cardiovascular conditions, as defined as any of the following: i) abnormal blood pressure, defined as: under 13y, 95th%ile +12 mm Hg or \\> 140\u002F90, whichever is lower; 13y and older, \\> 140\u002F90 ; ii) history of cardiac arrhythmia or arrhythmia detected on screening ECG; iii) history of heart failure and\u002For cardiomyopathy; iv) prolonged QTc interval (QTc \\> 460 msec), and\u002For long QT syndrome phenotype and\u002For positive genotype for long QT syndrome pathogenic; v) history of cardiac disease including coronary artery disease.\n8. Females who are pregnant, breastfeeding, or planning to become pregnant during the trial.\n9. \"Brittle\" diabetes insipidus (in the opinion of the referring endocrinologist, e.g. requiring frequent hospitalizations and\u002For frequent abnormal sodium values).\n10. Diabetes mellitus requiring insulin\u002Fsecretagogue. HbA1c \\> 8.5% at Screening.\n11. Clinically significant hyperthyroidism as assessed using thyroid hormone measurements. Clinical measurements within 12 months of baseline\u002Fscreening may be used to assess this criterion.\n12. History of clinically significant hypokalemia (low potassium) or current clinically significant hypokalemia (low potassium) on baseline\u002Fscreening labs.\n13. Clinically significant liver disease and\u002For known severe hepatic impairment. ALT \\> 3 x Upper Limit of Normal (ULN) AST \\> 3 x ULN\n14. Clinically significant kidney disease. GFR\\\u003C60 ml\u002Fmin\u002F1.73m2\n15. History of seizure in the 12 months prior to Screening.\n16. History of substance abuse, depression of moderate or greater severity, psychiatric disorder and\u002For suicidality.\n17. History of abdominal surgery including gastric bypass.\n18. Current use of supra-physiologic steroids.\n19. History of allergy or sensitivity to test agents. Including individuals with known aspirin allergy or hypersensitivity and\u002For known allergy to FD\\&C Yellow No. 5 (tartrazine).\n20. Concurrent use of carbonic anhydrase inhibitors.\n21. Concurrent use of non-potassium sparing diuretics.\n22. New weight management medication (or \\>5% decrease in weight over prior 2 months on any current, stable regimen), stimulant, and\u002For investigational medication within 2 months prior to screening, and\u002For plans to initiate other new weight management regimen.\n23. Cognitive impairment that, in the opinion of the investigator, precludes participation in the study.\n24. Individuals considered, in the Investigator's opinion, not suitable to participate in the study for reasons other than those indicated above.","6 Years","28 Years",{"count":136,"type":20},24,[61],"Hypothalamic obesity (HO) refers to the substantial weight gain that often complicates hypothalamic brain tumors. Children with this treatment-recalcitrant form of obesity have excess rates of metabolic sequelae compared to otherwise healthy children with similar obesity, and later experience excess mortality related to cardiometabolic disease. In this pilot trial, our objective is to gather key preliminary data about phentermine\u002Ftopiramate (Ph\u002FT) that is FDA-approved for \"common\" obesity but has never been tested in HO. The subset of individuals with HO who experience hyperphagia or excess daytime sleepiness may benefit from the Ph\u002FT-induced decrease in appetite and increase in alertness.\n\nPreliminary assessments of safety, adverse events, dosing (Aim 1), as well as of efficacy (% BMI loss, Aim 2) will be made in a 28-week parallel-arm double-blinded Phase 2 placebo-controlled clinical trial in 6-28-year-old individuals with HO.",[140,141,27],"Hypothalamic Obesity","Hypothalamic Tumor",[143,144,140,145],"Hypothalamic Lesion","Drug Intervention","Phentermine\u002FTopiramate","2025-07-23",{"date":148,"type":39},"2025-07-28",{"date":150,"type":39},"2025-03-01",{"date":152,"type":20},"2026-05-31",{"name":154,"class":46},"Seattle Children's Hospital",2,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":166,"conditions":167,"keywords":172,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":186},"100583292","the-impact-of-endoscopic-endonasal-skull-base-surgery-on-olfaction-100583292","NCT06874426","The Impact of Endoscopic Endonasal Skull Base Surgery on Olfaction","Endo-Olfact","Inclusion Criteria:\n\n* Adult patients scheduled for endoscopic endonasal skull base surgery\n\nExclusion Criteria:\n\n* Pre-existing anosmia\n* Patients has a history of previous endoscopic endonasal skull base surgery","70 Years",{"count":165,"type":20},154,"In this study, the research team will investigate the incidence and etiology of olfactory dysfunction following endoscopic endonasal skull base surgery, by combining clinical assessments with histomolecular analysis.",[168,169,26,27,170,171],"Meningioma","Pituitary Disease","Endoscopic Pituitary Surgery","Olfactory Dysfunction",[173,174,175,176],"olfactory dysfunction","trigeminal dysfunction","endoscopic endonasal skull base surgery","pituitary surgery","2025-04-17",{"date":179,"type":39},"2025-04-23",{"date":181,"type":39},"2025-03-18",{"date":183,"type":20},"2029-09",{"name":185,"class":46},"Universitaire Ziekenhuizen KU Leuven",3,{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":195,"minAge":16,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":47},"100577704","craniopharyngioma-and-pregnancies-100577704","NCT06801756","Craniopharyngioma and Pregnancies","Description of Pregnancies and Their Impact on the Craniopharyngioma","CRANIOGESTE","Inclusion Criteria:\n\n* Patients aged at least 18 years old\n* Patients with or having had a craniopharyngioma\n* Patients informed and not opposed to participation in research\n\nExclusion Criteria:\n\n* Patients who don't speak french\n* Patients without medical care insurance\n* Patients under legal protection","FEMALE",{"count":197,"type":20},100,"Craniopharyngiomas (CP) are rare hypothalamic-pituitary tumors found in young children, adolescents and adults. The management of PC remains complex, as their aggressive nature, invasive behavior and propensity to recur require sequential and balanced therapeutic attitudes, as well as follow-up in an expert center. Although patient survival rates are high, the consequences of the tumor and its treatment can lead to serious comorbidities and impaired quality of life, particularly in patients whose tumors extend to the hypothalamus. There is very little literature describing the outcome of pregnancy in craniopharyngioma patients and its impact on the craniopharyngioma. The largest study describes 6 women, mean age 24, who had a craniopharyngioma in childhood. Half of them had induced pregnancies; there is a succinct description of pregnancy complications and outcomes, as well as tumor progression.\n\nIn the endocrinology department of Pitié Salpêtrière hospital, the investigators regularly follow over a hundred patients of all ages who have presented with a craniopharyngioma in childhood or adulthood. They are also unique in having a medically assisted reproduction unit, which helps couples to realize their parental project. This dual specialization will enable to describe pregnancies and their impact on the behavior of craniopharyngiomas.",[27],[201],"pregnancy","2025-03-28",{"date":204,"type":39},"2025-04-02",{"date":206,"type":39},"2025-03-24",{"date":208,"type":20},"2026-03-24",{"name":102,"class":46},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":216,"targetDuration":218,"studyType":87,"phases":4,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":186},"100412277","proton-therapy-research-infrastructure--protrait--neuro-oncology-100412277","NCT04648462","Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology","Inclusion Criteria:\n\n1. All brain tumors with a favorable prognosis (median survival \\> 10 year)\n2. Age ≥ 18 years\n3. ECOG performance status 0 - 1 \u002F Karnofsky performance status 80 - 100\n4. No - minimal neurocognitive impairment\n5. Dosimetrical gain of protontherapy relative to photontherapy (≥5% on supratentorial brain dose or hippocampi)\n6. Informed consent\n\nExclusion Criteria:\n\n1. Not eligible for chemotherapy\n2. Eligible for stereotactic radiotherapy",{"count":217,"type":20},1500,"5 Years","The first proton therapy treatments in the Netherlands have taken place in 2018. Due to the physical properties of protons, proton therapy has tremendous potential to reduce the radiation dose to the healthy, tumour-surrounding tissues. In turn, this leads to less radiation-induced complications, and a decrease in the formation of secondary tumours. The Netherlands has spearheaded the development of the model-based approach (MBA) for the selection of patients for proton therapy when applied to prevent radiation-induced complications. In MBA, a pre-treatment in-silico planning study is done, comparing proton and photon treatment plans in each individual patient, to determine (1) whether there is a significant difference in dose in the relevant organs at risk (ΔDose), and (2) whether this dose difference translates into an expected clinical benefit in terms of NormalTissue Complication Probabilities (ΔNTCP). To translate ΔDose into ΔNTCP, NTCP-models are used, which are prediction models describing the relation between dose parameters and the likelihood of radiation-induced complications. The Dutch Society for Radiotherapy and Oncology (NVRO) setup the selection criteria for proton therapy in 2015, taking into account toxicity and NTCP. However, NTCP-models can be affected by changes in the irradiation technique. Therefore, it is paramount to continuously update and validate these NTCP-models in subsequent patient cohorts treated with new techniques. In ProTRAIT, a Findable, Accessible, Interoperable and Reusable (FAIR)data infrastructure for both clinical and 3D image and 3D dose information has been developed and deployed for proton therapy in the Netherlands. It allows for a prospective, standardized, multi-centric data from all Dutch proton and a representative group of photon therapy patients.",[221,222,223,224,225,168,226,227,27,228,229,230],"Astrocytoma","Ependymoma","Ganglioglioma","Oligodendroglioma","Optic Nerve Glioma","Nerve Sheath Neoplasms","Adenoma","Hemangiopericytoma","Germinoma","Neurilemmoma","2024-11-25",{"date":233,"type":39},"2024-11-26",{"date":235,"type":39},"2018-01-01",{"date":237,"type":20},"2035-01-01",{"name":239,"class":46},"Maastricht Radiation Oncology",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":21,"phases":250,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":47},"100479614","phase-2-treatment-of-braf--b-rapidly-accelerated-fibrosarcoma-mutated-papillary-craniopharyngioma-100479614","NCT05525273","Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma","Neoadjuvant and Postoperative Treatment With Dabrafenib and Trametinib in BRAF Mutated Papillary Craniopharyngioma","Swecranio","Inclusion Criteria:\n\n1. Histologically verified papillary craniopharyngioma.\n2. BRAF mutated V600E (valine 600 glutamine), verified immunohistochemically and by molecular genetic analysis\n3. Newly diagnosed tumor, or recurrence after previous surgery, where surgery is not considered to be able to be performed radically without the risk of serious or permanent sequelae.\n4. Age over 18 years\n5. Functional status according to ECOG (Eastern Cooperative Oncology Group performance status) 0-2\n6. Adequate organ function:\n\n   neutrophils\\> 1.5 x 109 platelets\\> 100 x 109 creatinine \\\u003C1.5 x ULN (upper limit of normal) or creatinine clearance \\\u003C45 ml \u002F min bilirubin \\\u003C1.5 x ULN ASAT (aspartate aminotransferase) \u002F ALAT (alanine aminotransferase) \\\u003C2.5 x ULN\n7. Ability to understand and give informed consent.\n8. Previous cancer, which does not require current treatment is allowed.\n9. The patient agrees to use an adequate method to avoid pregnancy.\n\nExclusion Criteria:\n\n1. Ongoing treatment in another drug study or other experimental treatment.\n2. Previous treatment with BRAF or MEK inhibitors.\n3. Hypersensitivity to study drugs.\n4. Ongoing treatment with non-authorized drugs, (strong inducers of CYP2C8 or CYP3A4). If the patient is on unauthorized drugs, they must be discontinued at least 14 days before inclusion.\n5. Known cardiovascular disease where treatment with MEK inhibitors is considered inappropriate, eg severe heart failure, prolongation of QT time, uncontrolled arrhythmia, recent (\\\u003C6 months) cardiac infarction, uncontrolled hypertension.\n6. Active bleeding; intracranial hemorrhage last 4 weeks before inclusion.\n7. Thromboembolic disease last 6 months and unstable anticoagulant treatment less than 4 weeks before inclusion.\n8. Women who are pregnant or breastfeeding.\n9. Previous central serous retinopathy or retinal vein occlusion.\n10. Previous uveitis or iritis last 4 weeks before inclusion.\n11. Surgery within the last 3 weeks.\n12. For postoperative patients; radiation therapy within the last 3 months.",{"count":249,"type":20},25,[61],"Subjects with papillary craniopharyngioma harboring a BRAF mutation will be treated with a BRAF + MEK inhibitor (dabrafenib + trametinib) after informed consent. Study participants will be administered oral dabrafenib and trametinib until maximal tumor volume reduction assessed by MRI. Progression free survival, cognition, ophthalmologic status, hypothalamic status and quality of life will be assessed 1 year after initiation of study treatment",[27],[254,255,256,257,258],"BRAF mutation","Dabrafenib","Trametinib","Neoadjuvant","Postoperative","2024-02-13",{"date":261,"type":39},"2024-02-14",{"date":263,"type":39},"2023-09-01",{"date":265,"type":20},"2028-04-10",{"name":267,"class":46},"Eva Marie Erfurth, MD, PhD"]